目的 研究丙戊酸鈉聯(lián)合帕利哌酮治療精神分裂癥的臨床療效。方法 選擇2014年4月—2016年1月到北京市昌平區(qū)中西醫(yī)結(jié)合醫(yī)院診治的精神分裂癥患者104例，隨機(jī)分為對(duì)照組和治療組，每組各52例。對(duì)照組口服帕利哌酮緩釋片，起始劑量為6 mg/d，1周內(nèi)根據(jù)病情將劑量調(diào)整為6～9 mg/d。治療組在對(duì)照組治療基礎(chǔ)上口服丙戊酸鈉緩釋片，起始劑量為0.5 g/d，最大劑量為1.5～2.0 g/d，可根據(jù)病情酌情加減。兩組患者均持續(xù)治療12周。觀察兩組的臨床療效，同時(shí)比較兩組治療前后陰性和陽性癥狀量表（PANSS）評(píng)分和個(gè)人和社會(huì)功能量表（PSP）評(píng)分的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.77%、94.23%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）治療后6、12周，兩組陽性癥狀評(píng)分、陰性癥狀評(píng)分、精神病理評(píng)分、PANSS總分顯著下降，PSP評(píng)分顯著升高，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且治療組這些評(píng)分的改善程度優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 丙戊酸鈉聯(lián)合帕利哌酮治療精神分裂癥療效顯著，有效緩解臨床癥狀，改善社會(huì)功能，安全性好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of sodiumvalproate combined with paliperidone in treatment of schizophrenia. Methods Patients (104 cases) with schizophrenia in Changping Hospital of Integrated Chinese and Western Medicine from April 2014 and January 2016 were randomly divided into control and treatment groups. Each group had 52 cases. The patients in the control group were po administered with Paliperidone Extended-Release Tablets, and the starting dosage was 0.5 g/d, than the dosage was adjusted to 1.5-2.0 mg/d according to condition of patients within 1 week. The patients in the treatment group were po administered with SodiumValproate Sustained Release Tablets on the basis of the control group, and the starting dosage was 1 mg/d, and the largest dosage was 4-6 mg/d, and the dosage was discretionary added and subtracted according to the illness condition. The patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the changes of PANSS scores and PSP scores in two groups before and after treatment were compared. Results After treatment, the total efficacies in the control and treatment groups were 80.77% and 94.23%, respectively, and there were differences between two groups (P<0.05). After treatment of 6 and 12 weeks, positive symptom score, negative symptom scores, psychiatric pathology scores, and PANSS total scores were significantly decreased, and PSP was significantly increased, the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sodiumvalproate combined with paliperidone has clinical curative effect in treatment of schizophrenia, and can relieve clinical symptoms effectively, also can improve social function with high safety, which has a certain clinical application value.